UK and Ireland dates
USA and Canada dates
Australia and NZ dates
Rest Of World dates
Featured Testimonials
THOR on Facebook
THOR on Twitter
THOR on LinkedIn
THOR on Instagram
THOR on YouTubeCategories
Essays
Links
Category Archives: Industry
THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)
Washington DC, 11th October, 2018. James Carroll (CEO, THOR Photomedicine), Prof. Praveen Arany (University at Buffalo, NY), Annette Quinn RN (Program Manager, Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced Photobiomodulation (PBM) to a large gathering of senior policy officials at the Rayburn House Office Building.
James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.
The briefing was a historic step for PBM, moving the conversation forward as members of congress were shown stories by members of the public on how PBM had impacted them and enabled them to live a life free from opioids.
The panel outlined the needs for PBM adoption as
- Research grants to fund further basic science experiments, therapeutic dose, and large multicenter … Continue reading
Posted in Industry, THE FUTURE OF PBM/LLLT
on THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)
LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe
LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care. The announcement follows the recent CE Mark Certification for the European Union (EU) for the treatment of dry AMD utilizing LumiThera’s Valeda™ Light Delivery System.
“The Distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “Optos is a global leader in ultra-widefield retinal imaging technologies and we are honored to be working with them to open up a new age in the treatment of AMD.”
Posted in Industry
on LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe
LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the EURETINA
LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Vienna, Austria from the 20th to the 26th of September 2018.
EURETINA actively promotes new diagnostic developments, advances in vitreoretinal surgery, the development and application of new drugs, and changes in the treatment of macular degeneration.
LumiThera will debut the Valeda™ Light Delivery System for the treatment of dry AMD in the exhibition hall and will host a symposium on PBM technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases” on September 20th.
Read the full press release:
LumiThera, Inc. to Debut Valeda … Continue reading
Posted in Industry
on LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the EURETINA
LumiThera LT-300 Device for treating Dry Advanced Macular Degeneration granted CE Mark
“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”
“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of life. The previous LIGHTSITE I Clinical Studies demonstrated that PBM therapy was most beneficial in early stage dry AMD patients. It was also determined that retreatments at scheduled intervals will be needed to maintain clinical benefits.”
Read the full press release:
LumiThera LT-300 Device For Treating Dry Advanced … Continue reading
Posted in Industry
on LumiThera LT-300 Device for treating Dry Advanced Macular Degeneration granted CE Mark
Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
RESULT: After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce some of the painful side effects of cancer treatments.
Read here: https://www.nice.org.uk/guidance/ipg615
Posted in Industry
on Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
The LIGHTSITE I data was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. Dr. Munk was part of the investigator team.
“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. Munk.
“Results from the LIGHTSITE I study following treatment with a multi-wavelength PBM treatment demonstrated clinical improvements in vision outcome measures providing a strong foundation for initial therapy as well as the need for follow-up maintenance therapy,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. … Continue reading
Posted in Industry
on LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
Shepherd University has introduced Photobiomodulation to their advanced practice nurses and faculty members
Shepherd University in partnership with the Photobiomodulation Therapy Foundation, announced its new health education initiative Wednesday during a day-long workshop, which introduced PBM, or photobiomodulation, to Shepherd’s advanced practice nurses and faculty members. It is considered the first step in bringing the application of light-based treatments into the nursing curriculum.
“PBM is important to West Virginians,” said Dr. Sharon Mailey, acting dean for and chair of the Department of Nursing Education, in a press release. “Our state leads the nation in opioid overdose deaths. PBM’s effectiveness in treating pain can create a viable alternative treatment that will help reduce dependence on addictive and dangerous medications.”
Read … Continue reading